

## ASX Release

### Appendix 4C – Q1 2025 Quarterly Cash Flow Report

24 April 2025 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 March 2025 (Q1 25) and provided an update on business activities.

#### Financial Highlights

Oneview’s cash balance at 31 March 2025 was €12.2 million (A\$21.0m) compared to €13.8 million (A\$23.2 million) at 31 December 2024.

The Company had a net cash outflow of €1.6m during the quarter compared to an outflow of €2.1 million in the same quarter of the prior year. The lower outflow is primarily due to strong customer receipts inflows in the first quarter of 2025 of €4.2 million compared to €2.6 million during same quarter of the prior year. Product manufacturing and operating costs were slightly higher in the quarter compared to the same quarter in the prior year due to greater deployment activity. The Company also had marginally higher staff and admin costs for the quarter compared to the same quarter in the prior year.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors’ fees and salaries totalling €321,000 (A\$538,000).

#### Operational Activities

##### *Sales and Customer Updates*

The Company is focused on continuing its strong momentum of adding new logos during 2025 by progressing its strong pipelines of Baxter and direct sales opportunities. We believe that the progress made during the first quarter of 2025 optimally positions the Company to maintain this momentum and achieve this goal.

The Company concluded what is always the busiest quarter of the year for lead generation with a series of high-profile conferences including Vive Health in Nashville, HIMSS and the Beryl Conference in Las Vegas, AONL in Boston and Australian Healthcare Week in Sydney.

These conferences reaffirmed the value proposition of bedside technology as the virtualisation of care theme continues to drive fresh engagement. The Company is in contract negotiations with four prospective customers including one of the top 10 health systems in the United States for a commercial pilot commencing in August.

As previously disclosed, our 2024 revenues were significantly impacted by the postponement of projects by a large customer due to corporate activity. The Company has recently received a purchase order from this customer for the deployment of Oneview into 280 beds in a new facility and engagement is progressing on re-initiating deployments across other facilities.

Implementation projects progressed at our existing customer sites, including:

- Deployments of the core platform, the digital door sign and the digital whiteboard continued during the first quarter of 2025 at Inova Health under the 1,900-bed Master Services Agreement which was signed in April 2024.
- The deployment project at the Rady Children's Health (formerly Children's Hospital of Orange County) also progressed during the quarter. Oneview's new product, MyStay Mobile, is being deployed alongside in-room televisions across inpatient and outpatients' points of care.
- Oneview's core platform and the digital whiteboard were also deployed at Care New England's new Brown University Labor and Delivery Center at Women & Infants Hospital which opened in March 2025.

#### *Product Updates*

During the quarter, the Company launched the first initiative from its Artificial Intelligence ("AI") Product Strategy, a Virtual Patient Assistant "alpha" product called Ovie. Ovie delivers on the continuous aim of Oneview to provide thoughtful innovation for our customers, combining efficiencies for nurses and improved and empowered care for the patients served by our technology. Customer pilots of Ovie will be progressed over the coming months followed by a targeted market launch during the second half of 2025.

Other product improvements during the quarter include:

- a Language Services API for one-touch access to interpreters at the bedside through compatible providers
- Bluetooth headphone support on touch devices
- a new Room Controls application using our new design system and enabling support for BACnet integration for compatible Building Management Systems
- enhancements to our Digital Door Sign and Digital Whiteboard based on customer feedback

#### *Outlook*

CEO James Fitter commented, "The Company enjoyed a particularly busy first quarter as Baxter jointly co-marketed our solution at several high-profile tradeshows across the United States. This engagement has reaffirmed the quality of the record pipeline of opportunities that are in flight, both directly and via the Baxter channel. The Company has not experienced any project delays as a result of the tariff changes proposed by the new US administration. Based on the current scope of the proposed tariffs, we expect the direct impact of the tariffs on our business to be limited to our current sourcing of some hardware items from China. Our strong levels of pre-tariff inventory of these items could be a strong competitive advantage as we face into a

more uncertain economic environment. Critically, our recurring software revenue will not be impacted."

**This announcement has been approved for release by the board of Oneview Healthcare plc.**

### **About Oneview Healthcare plc**

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oneview Healthcare PLC

**ABN**

610 611 768

**Quarter ended ("current quarter")**

 31<sup>st</sup> March 2025

<b>Consolidated statement of cash flows</b>	<b>Current quarter €'000</b>	<b>Year to date (3 months) €'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	4,234	4,234
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,411)	(1,411)
(c) advertising and marketing	(79)	(79)
(d) leased assets	-	-
(e) staff costs	(2,892)	(2,892)
(f) administration and corporate costs	(1,055)	(1,055)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	6	6
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	(1)	(1)
1.7 Government grants and tax incentives	-	-
1.8 Other (working capital movements)	(59)	(59)
<b>1.11 Net cash from / (used in) operating activities</b>	<b>(1,257)</b>	<b>(1,257)</b>

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	-	-

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	-	-

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	13,833	13,833
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(1,257)	(1,257)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	(384)	(384)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>12,192</b>	<b>12,192</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter €'000</b>	<b>Previous quarter €'000</b>
5.1	Bank balances	12,192	13,826
5.2	Call deposits	-	7
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>12,192</b>	<b>13,833</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter €'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	321
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. <b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end €'000</b>	<b>Amount drawn at quarter end €'000</b>
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 <b>Total financing facilities</b>	-	-
7.5 <b>Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. <b>Estimated cash available for future operating activities</b>	<b>€'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,257)
8.2 Cash and cash equivalents at quarter end (item 4.6)	12,192
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	12,192
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	9.7
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....24 April 2025.....

Authorised by: ..... **BY THE BOARD**.....  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.